Repercusiones de la dieta sobre la microbiota intestinal y la relación con efectos en la salud, eubiosis y disbiosis. Parte 3. Microbiota y enfermedades graves -medicina preventiva-, probióticos y prebióticos específicos
DOI:
https://doi.org/10.32399/icuap.rdic.2448-5829.2026.34.1680Palabras clave:
Microbiota intestinal, Ratas de la estirpe Wistar, Eubiosis, Disbiosis, Aditivos alimentarios, Sistema inmunológico, Desarrollo y funcionamiento del sistema inmuneResumen
La salud es un tema importante para la vida de los seres humanos y hasta relativamente pocos años se ha encontrado que la microbiota intestinal o flora microbiana que simbióticamente coexiste con ellos tiene una estrecha relación con la dieta y la salud holística del Homo sapiens. Por cuestiones éticas las ratas de la estirpe Wistar ha sido desde hace más de un siglo el objeto de estudio y en esta breve revisión bibliográfica dividida en tres partes, el objetivo global fue buscar las posibles relaciones de la dieta desde el nacimiento hasta la senectud sobre la microbiota intestinal. En la primera parte se abordaron sus efectos en el sistema inmunológico y digestivo y se buscaron estudios sobre organismos carentes de microbiota u “organismos libres de gérmenes” (“germ free” en inglés) desde el punto de vista de la salud. En la segunda parte se dio particular importancia a los estudios sobre los efectos sobre la microbiota intestinal de los aditivos alimentarios por sus amplias aplicaciones en la industria alimentaria y bebidas no alcohólicas, así como sobre cambios fisiológicos, metabólicos o nutrimentales provocados por diversas enfermedades que afectan la salud del hospedero o anfitrión. En la tercera parte se buscaron también estudios sobre probióticos y prebióticos específicos que mejoren o mantengan la eubiosis (equilibrio en la microbiota) y se dan pautas para mejorarla a través de la medicina preventiva. Pudo constatarse en estos tres enfoques que, para la primera parte, la dieta repercute en el desarrollo completo del tracto gastrointestinal desde el momento de nacer, así como en el funcionamiento del sistema inmunológico. Los organismos carentes de microbiota u “organismos libres de gérmenes” (“germ free” en inglés) tienen problemas de salud a lo largo de su vida. En la segunda parte, los aditivos alimentarios como los edulcorantes y los conservadores demostraron tener efectos negativos sobre la microbiota intestinal. La disbiosis intestinal puede promover desregulaciones en el organismo provocando inflamaciones sistémicas, así como enfermedades autoinmunes o mal funcionamiento inmunitario. Finalmente, en la tercera parte, se encontró que la inmunoregulación es de suma importancia para un sano funcionamiento del sistema inmune aún en individuos sanos mediante probióticos, prebióticos y alimentos especializados. Algunos estudios recomiendan que la medicina preventiva considere las relaciones entre la microbiota intestinal y el resto de los sistemas del hospedero (anfitrión).
Citas
Addou, S., Benaoumer, N., Bessalah, A., Mezemaze, F., Kheroua, O. 2015. Effet des prébiotiques sur la flore intestinale des rats Wistar. Revue Française d'Allergologie. 55(3): 238.
Arredondo, A., 2014. Type 2 diabetes and health care costs in Latin America: Exploring the need for greater preventive medicine. Bio-Medical Central Medicine. 12(1): 1-6. https://doi.org/10.1186/s12916-014-0136-z
Chandrasekar, T., Tang, J.C., Gao, A.C., Evans, C.P. 2015. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl. Androl. Urol. 4(3):365-380. doi: 10.3978/j.issn.2223-4683.2015.05.02
Chen, G.Q., Chen, Y.Y., Wang, X.S., Wu, S.Z., Yang, H.M., Xu, H.Q., He, J.C., Wang, X.T., Chen, J.F., Zheng, R.Y. 2009. Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats. Brain Research. 1309: 116-125. https://doi.org/10.1016/j.brainres.2009.10.054
Delgado-Venegas, C.S. 2018. Posible efecto modulador del probiótico Lactococcus lactis recombinante y silvestre sobre el daño hepático inducido por CCl4 en un modelo de rata Wistar. Tesis de maestría. Universidad Autónoma de Aguascalientes, Centro de Ciencias Básicas. Aguascalientes, México. http://bdigital.dgse.uaa.mx:8080/xmlui/bitstream/handle/11317/1604/433950.pdf?sequence=1&isAllowed=y
Di-Primio, A.N., Duca, G., Rubio, C. 2021. Actividad de los ‘fructooligosacáridos’ como prebiótico y efectos sobre el tracto intestinal. BioTecnología. 25(1): 10-20.
Ezendam, J., Baken, K., van Loveren, H. 2006. Immune effects of Lactobacillus casei Shirota. RIVM Reports. Pp. 1-52. Bilthoven, Países Bajos.
Faustino-Rocha, A.I., Jota-Baptista, C., Nascimento-Gonçalves, E., Oliveira P.A. 2023. Evolution of models of prostate cancer: Their contribution to current therapies. Anticancer Research. 43(1): 323-333. DOI: https://doi.org/10.21873/anticanres.16167
Ford, E.S. 2005. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic síndrome: A summary of the evidence. Diabetes Care. 28: 1769-1778. doi: 10.2337/diacare.28.7.1769
Gual-Grau, A. 2019. Gut microbiota dysbiosis in diet-induced obesity. A focus on the influence of genetics, circadian rhythms, and potential prebiotics. Tesis Doctoral. Universitat Rovira i Virgili, Facultad de Química. Tarragona, España.
Guilleminault, L., Ouksel, H., Belleguic, C., Le Guen, Y., Germaud, P., Desfleurs, E., Leroyer, C., Magnan, A. 2017. Personalised medicine in asthma: From curative to preventive medicine. European Respiratory Review. 26(143): 1-14. https://doi.org/10.1183/16000617.0010-2016
Gutiérrez, A., Contreras, C., Sánchez, A., Prieto, D. 2019. Role of phosphatidylinositol 3-Kinase (PI3K), mitogen activated protein kinase (MAPK), and protein kinase C (PKC) in calcium signaling pathways linked to the α1 (alpha)-adrenoceptor in resistance arteries. Front. Physiol. Vol. 10. https://doi.org/10.3389/fphys.2019.00055
Hansen, C.H.F., Nielsen, D.S., Kverka, M., Zakostelska, Z., Klimesova, K., Hudcovic, T., Tlaskalová-Hogenová, H., Hansen, A.K. 2012. Patterns of early gut colonization shape future immune responses of the host. PLoS ONE. 7(3): e34043. https://doi.org/10.1371/journal.pone.0034043
Harguindey, S. 2004. Apoptosis y antiapoptosis en cáncer, Alzheimer y procesos neurodegenerativos: ¿Una dialéctica de contrarios? Nuevo abanico de posibilidades terapéuticas y peligros potenciales. Oncología (Barcelona). 27(10): 579-589.
Hart, A.L., Lammers, K., Brigidi, P., Vitali, B., Rizzello, F., Gionchetti, P., Campieri, M., Kamm, M.A., Stagg, A.J. 2004. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut. 53(11): 1602-1609. https://doi.org/10.1136/gut.2003.037325
INEGI. 2022. Estadística de defunciones registradas de enero a junio de 2021 (preliminar). https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2022/dr/dr2021.pdf
Kustrimovic, N., Bombelli, R., Baci, D., Mortara, L. 2023. Microbiome and prostate cancer: A novel target for prevention and treatment. International Journal of Molecular Sciences. 24(2): 1511. doi: 10.3390/ijms24021511
Lollo, P.C.B., Cruz, A.G., Morato, P.N., Moura, C.S., Carvalho-Silva, L.B., Oliveira, C.A. Faria, J.A.F., Amaya-Farfan, J. 2012. Probiotic cheese attenuates exercise-induced immune suppression in Wistar rats. Journal of Dairy Science. 95(7): 3549-3558.
López-Marín, L.M., Valdemar-Aguilar, C.M. 2020. Patrones moleculares asociados a patógenos: ¿Héroes o villanos en nanomedicina? / Molecular patterns associated with pathogens: Heroes or villains in nanomedicine? Mundo nano. Revista interdisciplinaria en nanociencias y nanotecnología. 11(20): 53-63. https://doi.org/10.22201/ceiich.24485691e.2018.20.62595
Marques, C., Meireles, M., Norberto, S., Leite, J., Freitas, J., Pestana, D., Faria, A., Calhau, C. 2015. High-fat diet-induced obesity Rat model: A comparison between Wistar and Sprague Dawley rat. Adipocyte. 5: 1–11. https://doi.org/10.1080/21623945.2015.1061723
Marrack, P., Kappler, J., Kotzin, B.L. 2001. Autoimmune disease: Why and where it occurs. Nature Medicine. 7(8): 899-905. https://doi.org/10.1038/90935
Mayo Clinic. 2024. ¿Qué son los probióticos y los prebióticos? Respuesta de Katherine Zeratsky, RD, LD. [RD significa en inglés Registered Dietitian (Dietista registrado) y LD o LDN es para Licensed Dietitian (Nutritionist) (Licenciado Dietista y Nutricionista), indicando que la persona tiene licencia legal para ejercer en su estado los estudios que realizó] https://www.mayoclinic.org/es/healthy-lifestyle/nutrition-and-healthy-eating/expert-answers/probiotics/faq-20058065#:~:text=Los%20probi%C3%B3ticos%20son%20alimentos%20o,nutrientes%20para%20la%20microbiota%20humana.
McLean, M.H., Dieguez, D., Miller, L.M., Young, H.A. 2015. Does the microbiota play a role in the pathogenesis of autoimmune diseases. Gut. 64(2): 332-341. http://dx.doi.org/10.1136/gutjnl-2014-308514
Messora, M.R., Oliveira, L.F.F., Foureaux, R.C., Taba Jr, M., Zangerônimo, M.G., Furlaneto, F.A.C., Pereira, L.J. 2013. Probiotic therapy reduces periodontal tissue destruction and improves the intestinal morphology in rats with ligature‐induced periodontitis. Journal of Periodontology. 84(12): 1818-1826. https://doi.org/10.1902/jop.2013.120644
Nagpal, R., Yadav, H., Marotta, F. 2014. Gut microbiota: The next-gen frontier in preventive and therapeutic medicine? Frontiers in Medicine. 1: 1-15. https://doi.org/10.3389/fmed.2014.00015
Negrete-Lira, S. 2022. Repercusiones de la microbiota intestinal y la dieta en el desarrollo y maduración del sistema inmunológico en ratas hembra y macho de la estirpe Wistar”. Tesis profesional (Química de Alimentos). Universidad Nacional Autónoma de México, UNAM. Facultad de Química. Ciudad de México, México. 132.248.9.195/ptd2022/noviembre/0833114/Index.html
Neu, J., Reverte, C.M., Mackey, A.D., Liboni, K., Tuhacek-Tenace, L.M., Hatch, M., Li, N., Caicedo, R.A., Schatz, D.A., Atkinson, M. 2005. Changes in intestinal morphology and permeability in the biobreeding rat before the onset of type 1 diabetes. Journal of Pediatric Gastroenterology and Nutrition. 40(5): 589-595. https://doi.org/10.1097/01.mpg.0000159636.19346.c1
Neyrinck, A., Possemiers, S., Verstraete, W., De Backer, F., Cani, P., Delzenne, N. 2012. Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice. Journal of Nutritional Biochemistry. 23: 51-59.
https://doi.org/10.1016/j.jnutbio.2010.10.008
Noor, N.A., Fahmy, H.M., Mohammed, F.F., Elsayed, A.A., Radwan, N.M. 2015. Nigella sativa ameliorates inflammation and demyelination in the experimental autoimmune encephalomyelitis-induced Wistar rats. International Journal of Clinical and Experimental Pathology. 8(6): 6269-6286.
OMS. 2020. Las 10 principales causas de defunción. https://www.who.int/es/news-room/fact-sheets/detail/the-top-10-causes-of-death. [Fecha de consulta 03/09/2022].
Oseni, S.O., Naar, C., Pavlović, M., Asghar, W., Hartmann, J.X., Fields, G.B., Esiobu, N., Kumi-Diaka, J. 2023. The molecular basis and clinical consequences of chronic inflammation in prostatic diseases: Prostatitis, benign prostatic hyperplasia, and prostate cancer. Cancers. 15(12): 3110. https://doi.org/10.3390/cancers15123110
Paule, A., Frezza, D., Edeas, M. 2018. Microbiota and phage therapy: Future challenges in medicine. Medical Sciences. 6(4): 86. https://doi.org/10.3390/medsci6040086
Pedroza-Pacheco, I., Madrigal, A., Saudemont, A. 2013. Interaction between natural killer cells and regulatory T cells: Perspectives for immunotherapy. Cellular & Molecular Immunology. 10(3):222–229. doi: 10.1038/cmi.2013.2
Rasool, R., Ullah, I., Shahid, S., Mubeen, B., Imam, S.S., Alshehri, S., Ghoneim M.M., Alzarea, S.I., Murtaza, B.N., Nadeem, M.S., Kazmi, I. 2022. In vivo assessment of the ameliorative impact of some medicinal plant extracts on lipopolysaccharide-induced multiple sclerosis in Wistar rats. Molecules. 27(5): 1608. https://doi.org/10.3390/molecules27051608
Reyes-Pavón, D. 2020. Efecto del glicomacropéptido, solo o combinado con Lactobacillus rhamnosus, sobre las alergias alimenticias en un modelo experimental. Tesis doctoral. Universidad Autónoma de Aguascalientes, Centro de Ciencias Básicas. Aguascalientes, México.
Ruiz-Iglesias, P., Estruel-Amades, S., Camps-Bossacoma, M., Massot-Cladera, M., Castell, M., Pérez-Cano, F. J. 2020. Alterations in the mucosal immune system by a chronic exhausting exercise in Wistar rats. Scientific Reports. 10(1): 1-14. https://doi.org/10.1038/s41598-020-74837-9
Scrimini, S., Pons, J., Sauleda, J. 2015. Células mieloides supresoras: Potencial vínculo entre la enfermedad pulmonar obstructiva crónica y el cáncer de pulmón / Myeloid-derived suppressor cells: Possible link between chronic obstrucive pulmonary disease and lung cancer. Archivos de Bronconeumología. 52(1): 29-35. DOI: 10.1016/j.arbres.2015.07.003
Squires, M.S., Hudson, E.A., Howells, L., Sale, S., Houghton, C.E., Jones, J.L., Fox, L.H., Dickens, M., Prigent, S.A., Manson, M.M. 2003. Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochemical Pharmacology. 65(3): 361-376. https://doi.org/10.1016/S0006-2952(02)01517-4
Tlaskalová-Hogenová, H., Štěpánková, R., Kozáková, H., Hudcovic, T., Vannucci, L., Tučková, L., Rossmann, P., Hrnčíř, T., Kverka, M., Zakostelská, Z., Klimešová, K., Přibylová, J., Bártová, J., Sanchez, D., Fundová, P., Borovská, D., Šrůtková, D., Zídek, Z., Schwarzer, M., Drastich, P., Funda, D. P. 2011. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cellular & Molecular Immunology. 8(2): 110-120. https://doi.org/10.1038/cmi.2010.67
Torres-Pérez, A.A. 2021. Identificación protéomica de patrones moleculares asociados a daño durante la progresión clínica de la periodontitis. Tesis de Magíster en Ciencias Odontológicas mención Periodontología. Universidad de Chile, Facultad de Odontología. Santiago, Chile.
Velloso, L.A., Folli, F., Saad, M.J. 2015. TLR4 en la encrucijada de los nutrientes, la microbiota intestinal y la inflamación metabólica. Endocrine Reviews. 36: 245271.
Wang, F. 2018. The roles of preventive and curative health care in economic development. Public Library of Science ONE. 13(11): 1-12. https://doi.org/10.1371/journal.pone.0206808
WHO. 2022. Cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/cancer [Last accessed on November 13, 2022]
Yamada, Y., Beltrán, H. 2021. Características clínicas y biológicas del cáncer neuroendocrino de próstata. Curr. Oncol. Rep. 23(2):15. doi: 10.1007/s11912-020-01003-9
Yamamoto-Furusho, J.K., Sánchez-Morales, G.E., García-Rangel, D., Vargas-Alarcón, G. 2016. Polimorfismos genéticos de interleucina-22 en pacientes con colitis ulcerosa / Genetic polymorphisms of interleukin-22 in patients with ulcerative colitis. Revista de Gastroenterología de México. 81(2): 86-90. https://doi.org/10.1016/j.rgmx.2016.02.002
Citas del texto descrito en este documento basado en Oseni, S.O., Naar, C., Pavlović, M., Asghar, W., Hartmann, J.X., Fields, G.B., Esiobu, N., Kumi-Diaka, J. 2023. The molecular basis and clinical consequences of chronic inflammation in prostatic diseases: Prostatitis, benign prostatic hyperplasia, and prostate cancer. Cancers. 15(12): 3110. https://doi.org/10.3390/cancers15123110
Shrestha, E.; White, J.R.; Yu, S.H.; Kulac, I.; Ertunc, O.; De Marzo, A.M.; Yegnasubramanian, S.; Mangold, L.A.; Partin, A.W.; Sfanos, K.S. Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J. Urol. 2018, 199, 161–171.
Cui, L.; Morris, A.; Ghedin, E. The Human Mycobiome in Health and Disease. Genome Med. 2013, 5, 63.
Eloe-Fadrosh, E.A.; Rasko, D.A. The Human Microbiome: From Symbiosis to Pathogenesis. Annu. Rev. Med. 2013, 64, 145-163.
Harmon, K. Bugs Inside: What Happens When the Microbes That Keep Us Healthy Disappear? Scientific American, 16 December 2009.
Human Microbiome Project Consortium. A Framework for Human Microbiome Research. Nature 2012, 486, 215–221.
Kidane, D.; Chae, W.J.; Czochor, J.; Eckert, K.A.; Glazer, P.M.; Bothwell, A.L.M.; Sweasy, J.B. Interplay between DNA Repair and Inflammation, and the Link to Cancer. Crit. Rev. Biochem. Mol. Biol. 2014, 49, 116-139.
Massari, F.; Mollica, V.; Di Nunno, V.; Gatto, L.; Santoni, M.; Scarpelli, M.; Cimadamore, A.; Lopez-Beltran, A.; Cheng, L.; Battelli, N.; Montironi, R.; Brandi, G. The human microbiota and prostate cancer: Friend or foe? Cancers 2019, 11, 459.
Francescone, R.; Hou, V.; Grivennikov, S.I. Microbiome, inflammation, and cancer. Cancer J. 2014, 20, 181.
Feng, X.; Han, L.; Ma, S.; Zhao, L.; Wang, L.; Zhang, K.; Yin, P.; Guo, L.; Jing, W.; Li, Q. Microbes in tumoral in situ tissues and in tumorigenesis. Front. Cell. Infect. Microbiol. 2020, 10, 572570.
Markowski, M.C.; Boorjian, S.A.; Burton, J.P.; Hahn, N.M.; Ingersoll, M.A.; Vareki, S.M.; Pal, S.K.; Sfanos, K.S. The microbiome and genitourinary cancer: A collaborative review. Eur. Urol. 2019, 75, 637–646.
Zackular, J.P.; Baxter, N.T.; Iverson, K.D.; Sadler, W.D.; Petrosino, J.F.; Chen, G.Y.; Schloss, P.D. The gut microbiome modulates colon tumorigenesis. mBio. 2013, 4, e00692-13.
Katongole, P.; Sande, O.J.; Joloba, M.; Reynolds, S.J.; Niyonzima, N. The human microbiome and its link in prostate cancer risk and pathogenesis. Infect. Agent Cancer 2020, 15, 53.
Cavarretta, I.; Mancini, N.; Salonia, A. Analysis of the enteric microbiome: First tentative steps towards a comprehensive work-up of prostate cancer? Eur. Urol. 2018, 74, 583–584.
Cavarretta, I.; Ferrarese, R.; Cazzaniga, W.; Saita, D.; Lucianò, R.; Ceresola, E.R.; Locatelli, I.; Visconti, L.; Lavorgna, G.; Briganti, A.; Nebuloni, M.; Doglioni, C.; Clementi, M.; Montorsi, F.; Canduci, F.; Salonia, A. The microbiome of the prostate tumor microenvironment. Eur. Urol. 2017, 72, 625–631.
Miyake, M.; Ohnishi, K.; Hori, S.; Nakano, A.; Nakano, R.; Yano, H.; Ohnishi, S.; Owari, T.; Morizawa, Y.; Itami, Y.; Nakai, Y.; Inoue, T.; Anai, S.; Torimoto, K.; Tanaka, N.; Fujii, T.; Furuya, H.; Rosser, C.J.; Fujimoto, K. Mycoplasma genitalium infection and chronic inflammation in human prostate cancer: Detection using prostatectomy and needle biopsy specimens. Cells. 2019, 8, 212.
Liss, M.A.; White, J.R.; Goros, M.; Gelfond, J.; Leach, R.; Johnson-Pais, T.; Lai, Z.; Rourke, E.; Basler, J.; Ankerst, D.; Shah, D.P. Metabolic biosynthesis pathways identified from fecal microbiome associated with prostate cancer. Eur. Urol. 2018, 74, 575–582.
Xuan, C.; Shamonki, J.M.; Chung, A.; DiNome, M.L.; Chung, M.; Sieling, P.A.; Lee, D.J. Microbial dysbiosis is associated with human breast cancer. PLoS ONE 2014, 9, e83744.
Elkahwaji, J.E.; Hauke, R.J.; Brawner, C.M. Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate. Br. J. Cancer. 2009, 101, 1740–1748.
Liberti, M.V.; Locasale, J.W. The Warburg effect: How does it benefit cancer cells? Trends Biochem. Sci. 2016, 41, 211–218.
Duncan, S.H.; Louis, P.; Flint, H.J. Cultivable bacterial diversity from the human colon. Lett. Appl. Microbiol. 2007, 44, 343–350.
Bullman, S.; Pedamallu, C.S.; Sicinska, E.; Clancy, T.E.; Zhang, X.; Cai, D.; Neuberg, D.; Huang, K.; Guevara, F.; Nelson, T.; Chipashvili, O.; Hagan, T.; Walker, M.; Ramachandran, A.; Diosdado, B.; Serna, G.; Mulet, N.; Landolfi, S.; Ramón-y-Cajal, S.; Fasani, R.; Aguirre, A.J.; Ng, K.; Élez, E.; Ogino, S.; Tabernero, J.; Fuchs, C.S.; Hahn, W.C.; Nuciforo, P.; Meyerson, M. Analysis of fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017, 358, 1443–1448.
Rybak, A.P.; He, L.; Kapoor, A.; Cutz, J.C.; Tang, D. Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. Biochim. Biophys. Acta Mol. Cell Res. 2011, 1813, 683–694.
Yun, E.-J.; Lo, U.-G.; Hsieh, J.-T. The evolving landscape of prostate cancer stem cell (PCSC): Therapeutic implications and future challenges. Asian J. Urol. 2016, 3, 203–210.
Menendez, J.A.; Alarcón, T. Metabostemness: A new cancer hallmark. Front. Oncol. 2014, 4, 262.
Shi, X.; Zhang, Y.; Zheng, J.; Pan, J. Reactive oxygen species in cancer stem cells. Antioxid. Redox Signal. 2012, 16, 1215–1228.
Oseni, S.O.; Kwasi Kumi-Diaka, J. emerging role of cancer stemness in prostate cancer recurrence and management. Acta Sci. Cancer Biol. 2018, 2, 2–5.
Chen, K.; Huang, Y.; Chen, J. Understanding and targeting cancer stem cells: Therapeutic implications and challenges. Acta Pharmacol. Sin. 2013, 34, 732–740.
Rowehl, R.A.; Crawford, H.; Dufour, A.; Ju, J.; Botchkina, G.I. Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line. Cancer Genom. Proteom. 2008, 5, 301–310.
Citas del artículo Faustino-Rocha, A.I., Jota-Baptista, C., Nascimento-Gonçalves, E., Oliveira P.A. 2023. Evolution of models of prostate cancer: Their contribution to current therapies. Anticancer Research. 43(1): 323-333. DOI: https://doi.org/10.21873/anticanres.16167 donde se plantearon como pregunta de investigación qué modelos están disponibles para el estudio y la solución deseable del cáncer.
References
WHO. 2022. Cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/cancer [Last accessed on November 13, 2022]
Moore RA, Melchionna RH. 1937. Production of tumors of the prostate of the white rat with 1:2-benzpyrene. Am J Cancer 30: 731-741, 1937. Abstract/FREE Full TextGoogle Scholar
Dunning WF, Curtis MR and Segaloff A. 1946. Methylcholanthrene squamous cell carcinoma of the rat prostate with skeletal metastases, and failure of the rat liver to respond to the carcinogen. Cancer Res 6: 256-262, 1946. PMID: 21024837. FREE Full TextGoogle Scholar
Pour PM. 1981. A new prostatic cancer model: systemic induction of prostatic cancer in rats by a nitrosamine. Cancer Lett 13(4): 303-308, 1981. PMID: 6171336. DOI: 10.1016/0304-3835(81)90058-6. CrossRefPubMedGoogle Scholar
Bosland MC. 1996. Chemical and hormonal induction of prostate cancer in animal models. Urol Oncol 2(4): 103-110, 1996. PMID: 21224148. DOI: 10.1016/s1078-1439(97)82840-2. CrossRefPubMedGoogle Scholar
Katayama S, Fiala E, Reddy BS, Rivenson A, Silverman J, Williams GM and Weisburger JH. 1982. Prostate adenocarcinoma in rats: induction by 3,2′-dimethyl-4-aminobiphenyl. J Natl Cancer Inst 68(5): 867-873, 1982. PMID: 6951094. CrossRefPubMedGoogle Scholar
Shirai T, Sano M, Tamano S, Takahashi S, Hirose M, Futakuchi M, Hasegawa R, Imaida K, Matsumoto K, Wakabayashi K, Sugimura T and Ito N. 1997. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res 57(2): 195-198, PMID: 9000552.
Abstract/FREE Full TextGoogle Scholar
Samy RP, Rajendran P, Li F, Anandi NM, Stiles BG, Ignacimuthu S, Sethi G and Chow VT. 2012. Identification of a novel Calotropis procera protein that can suppress tumor growth in breast cancer through the suppression of NF-ĸB pathway. PLoS One 7(12): e48514, PMID: 23284617. DOI: 10.1371/journal.pone.0048514
CrossRefPubMedGoogle Scholar
Nascimento-Gonçalves E, Faustino-Rocha AI, Seixas F, Ginja M, Colaço B, Ferreira R, Fardilha M and Oliveira PA. 2018. Modelling human prostate cancer: Rat models. Life Sci 203: 210-224, PMID: 29684445. DOI: 10.1016/j.lfs.2018.04.014. CrossRefPubMedGoogle Scholar
Shirai T, Takahashi S, Cui L, Futakuchi M, Kato K, Tamano S and Imaida K. 2000. Experimental prostate carcinogenesis - rodent models. Mutat Res 462(2-3): 219-226, PMID: 10767633. DOI: 10.1016/s1383-5742(00)00039-9. CrossRefPubMedGoogle Scholar
Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM and Cardiff RD. 2004. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64(6): 2270-2305, PMID: 15026373. DOI: 10.1158/0008-5472.can-03-0946. Abstract/FREE Full TextGoogle Scholar
Bosland MC. 1992. Animal models for the study of prostate carcinogenesis. J Cell Biochem Suppl 16H: 89-98, PMID: 1289679. DOI: 10.1002/jcb.240501221
CrossRefPubMedGoogle Scholar
Nascimento-Gonçalves E, Seixas F, Ferreira R, Colaço B, Parada B and Oliveira PA. 2021. An overview of the latest in state-of-the-art murine models for prostate cancer. Expert Opin Drug Discov 16(11): 1349-1364, PMID: 34224283. DOI: 10.1080/17460441.2021.1943354. CrossRefPubMedGoogle Scholar
Nascimento-Gonçalves E, Ferreira R, Oliveira PA and Colaço BJA. 2020. An overview of current alternative models for use in the context of prostate cancer research. Altern Lab Anim 48(2): 58-69, PMID: 32614643. DOI: 10.1177/0261192920929701. CrossRefPubMedGoogle Scholar
Tennant TR, Kim H, Sokoloff M and Rinker-Schaeffer CW. 2000. The Dunning model. Prostate 43(4): 295-302, PMID: 10861749. DOI: 10.1002/1097-0045(20000601)43:4<295::aid-pros9>3.0.co;2-w. CrossRefPubMedGoogle Scholar
Pollard M. 1973. Spontaneous prostate adenocarcinomas in aged germfree Wistar rats. J Natl Cancer Inst 51(4): 1235-1241, PMID: 4745857. DOI: 10.1093/jnci/51.4.1235
CrossRefPubMedGoogle Scholar
Shain SA, McCullough B and Segaloff A. 1975. : Spontaneous adenocarcinomas of the ventral prostate of aged A X C rats. J Natl Cancer Inst 55(1): 177-180, PMID: 1159811. DOI: 10.1093/jnci/55.1.177. CrossRefPubMedGoogle Scholar
Isaacs JT. 1984. The aging ACI/Seg versus Copenhagen male rat as a model system for the study of prostatic carcinogenesis. Cancer Res 44(12 Pt 1): 5785-5796, PMID: 6498839. Abstract/FREE Full TextGoogle Scholar
Bosland MC. 1996. Chemical and hormonal induction of prostate cancer in animal models. Urol Oncol 2(4): 103-110, PMID: 21224148. DOI: 10.1016/s1078-1439(97)82840-2. CrossRefPubMedGoogle Scholar
Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE, Kelloff GJ and McCormick DL. 1999. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res 59(13): 3084-3089, PMID: 10397249. Abstract/FREE Full TextGoogle Scholar
Bosland MC. 1996. Chemical and hormonal induction of prostate cancer in animal models. Urol Oncol 2(4): 103-110, PMID: 21224148. DOI: 10.1016/s1078-1439(97)82840-2. CrossRefPubMedGoogle Scholar
Shirai T, Tada M, Kojima M, Hasegawa R, Masui T and Ito N. 1994. DNA adducts in target and nontarget tissues of 3,2′-dimethyl-4-aminobiphenyl in rats. Environ Health Perspect 102 Suppl 6(Suppl 6): 167-172, PMID: 7889841. DOI: 10.1289/ehp.94102s6167. CrossRefPubMedGoogle Scholar
Takayama K, Yamashita K, Wakabayashi K, Sugimura T and Nagao M. 1989. DNA modification by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in rats. Jpn J Cancer Res 80(12): 1145-1148, PMID: 2516840. DOI: 10.1111/j.1349-7006.1989.tb01644.x. CrossRefPubMedGoogle Scholar
Snyderwine EG, Venugopal M and Yu M. 2002. Mammary gland carcinogenesis by food-derived heterocyclic amines and studies on the mechanisms of carcinogenesis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Mutat Res 506-507: 145-152, PMID: 12351154. DOI: 10.1016/s0027-5107(02)00161-6 CrossRefPubMedGoogle Scholar
Tang MX, Ogawa K, Asamoto M Chewonarin T, Suzuki S, Tanaka T and Shirai T. 2011. Effects of nobiletin on PhIP-induced prostate and colon carcinogenesis in F344 rats. Nutr Cancer 63(2): 227-233, PMID: 21298591. DOI: 10.1080/01635581.2011.523506. CrossRefPubMedGoogle Scholar
Naiki-Ito A, Chewonarin T, Tang M, Pitchakarn P, Kuno T, Ogawa K, Asamoto M, Shirai T and Takahashi S. 2015. Ellagic acid, a component of pomegranate fruit juice, suppresses androgen-dependent prostate carcinogenesis via induction of apoptosis. Prostate 75(2): 151-160, PMID: 25284475. DOI: 10.1002/pros.22900. CrossRefPubMedGoogle Scholar
Canene-Adams K, Sfanos KS, Liang CT, Yegnasubramanian S, Nelson WG, Brayton C and De Marzo AM. 2013. Dietary chemoprevention of PhIP induced carcinogenesis in male Fischer 344 rats with tomato and broccoli. PLoS One 8(11): e79842, PMID: 24312188. DOI: 10.1371/journal.pone.0079842. CrossRefPubMedGoogle Scholar
Lawson TA, Gingell R, Nagel D, Hines LA and Ross A. 1981. Methylation of hamster DNA by the carcinogen N-nitroso-bis (2-oxopropyl)amine. Cancer Lett 11(3): 251-255, PMID: 7248930. DOI: 10.1016/0304-3835(81)90116-6. CrossRefPubMedGoogle Scholar
Johannsen M, Thiesen B, Jordan A, Taymoorian K, Gneveckow U, Waldöfner N, Scholz R, Koch M, Lein M, Jung K and Loening SA. 2005. Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model. Prostate 64(3): 283-292, PMID: 15726645. DOI: 10.1002/pros.20213. CrossRefPubMedGoogle Scholar
McCullough DJ, Stabley JN, Siemann DW and Behnke BJ. 2014. Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. J Natl Cancer Inst 106(4): dju036, PMID: 24627275. DOI: 10.1093/jnci/dju036. CrossRefPubMedGoogle Scholar
McCullough DJ, Nguyen LM, Siemann DW and Behnke BJ. 1985. Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model. J Appl Physiol 115(12): 1846-1854, 2013. PMID: 24177690. DOI: 10.1152/japplphysiol.00949.2013. CrossRefPubMedGoogle Scholar
Neubauer BL, Bemis KG, Best KL, Goode RL, Merriman RL, Smith GF, Tanzer LR and Hoover DM. 1986. Metastatic spread of the PAIII prostatic adenocarcinoma after implantation in the tail of the rat. Prostate 8(3): 265-276, PMID: 3703746. DOI: 10.1002/pros.299008030. CrossRefPubMedGoogle Scholar
Johnson LE, Becker JT, Dubovsky JA, Olson BM and McNeel DG. 2012. Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments. Chin Clin Oncol 2(1): doi:10.3978/j.issn.2304-3865. 11.06, 2013. PMID: 24324949. DOI: 10.3978/j.issn.2304-3865.2012.11.06. CrossRefPubMedGoogle Scholar
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM and Cornford P. 2021. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2): 243-262, PMID: 33172724. DOI: 10.1016/j.eururo.2020.09.042. CrossRefPubMedGoogle Scholar
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, der Kwast THV, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, der Poel HGV, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM and Mottet N. 2021. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer. Eur Urol 79(2): 263-282, PMID: 33039206. DOI: 10.1016/j.eururo.2020.09.046. CrossRefPubMedGoogle Scholar
Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, Tombal B, Gillessen S and ESMO Guidelines Committee. 2020. : Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(9): 1119-1134, PMID: 32593798. DOI: 10.1016/j.annonc.2020.06.011. CrossRefPubMedGoogle Scholar
Basiri A, de la Rosette JJ, Tabatabaei S, Woo HH, Laguna MP and Shemshaki H. 2018. Comparison of retropubic, laparoscopic and robotic radical prostatectomy: who is the winner? World J Urol 36(4): 609-621, PMID: 29362896. DOI: 10.1007/s00345-018-2174-1. CrossRefPubMedGoogle Scholar
Wang JW and Man LB. 2020. Transurethral resection of the prostate stricture management. Asian J Androl 22(2): 140-144, PMID: 31898584. DOI: 10.4103/aja.aja_126_19. CrossRefPubMedGoogle Scholar
Jaymand M, Davatgaran Taghipour Y, Rezaei A, Derakhshankhah H, Foad abazari M, Samadian H and Hamblin M. 2022. Radiolabeled carbon-based nanostructures: New radiopharmaceuticals for cancer therapy? Coordination Chemistry Reviews 440: 213974, DOI: 10.1016/j.ccr.2021.213974. CrossRefGoogle Scholar
FDA approves pluvicto for metastatic castration-resistant prostate cancer | FDA. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer [Last accessed on November 13, 2022]. Google Scholar
Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K and Haberkorn U. 2016. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med 57(8): 1170-1176, PMID: 26985056. DOI: 10.2967/jnumed.115.171397. Abstract/FREE Full TextGoogle Scholar
Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, Kong G, Kumar AR, Thang SP, Eu P, Scalzo M, Murphy D, Williams S, Hicks RJ and Hofman MS. 2019. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med 60(4): 517-523, PMID: 30291192. DOI: 10.2967/jnumed.118.219352. Abstract/FREE Full TextGoogle Scholar
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ and VISION Investigators. 2021. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12): 1091-1103, PMID: 34161051. DOI: 10.1056/NEJMoa2107322. CrossRefPubMedGoogle Scholar
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ and SPARTAN Investigators. 2018. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15): 1408-1418, PMID: 29420164. DOI: 10.1056/NEJMoa1715546. CrossRefPubMedGoogle Scholar
FDA. Novel Drug Approvals for 2018. Available at: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018 [Last accessed on November 13, 2022]. Google Scholar
Erleada | European Medicines Agency. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/erleada [Last accessed on November 13, 2022]. Google Scholar
Nubeqa | European Medicines Agency. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa [Last accessed on November 13, 2022]. Google Scholar
FDA approves darolutamide for non-metastatic castration-resistant prostate cancer | FDA. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer [Last accessed on November 13, 2022]. Google Scholar
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B and ARASENS Trial Investigators. 2022. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386(12): 1132-1142, PMID: 35179323. DOI: 10.1056/NEJMoa2119115. CrossRefPubMedGoogle Scholar
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR and ARAMIS Investigators. 2020. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 383(11): 1040-1049, PMID: 32905676. DOI: 10.1056/NEJMoa2001342. CrossRefPubMedGoogle Scholar
Valerio M, Dickinson L, Ali A, Ramachandran N, Donaldson I, Freeman A, Ahmed HU and Emberton M. 2014. A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT). Contemp Clin Trials 39(1): 57-65, PMID: 25072507. DOI: 10.1016/j.cct.2014.07.006. CrossRefPubMedGoogle Scholar
Al-Sakere B, André F, Bernat C, Connault E, Opolon P, Davalos RV, Rubinsky B and Mir LM. 2007. Tumor ablation with irreversible electroporation. PLoS One 2(11): e1135, 2007. PMID: 17989772. DOI: 10.1371/journal.pone.0001135. CrossRefPubMedGoogle Scholar
Ong S, Leonardo M, Chengodu T, Bagguley D and Lawrentschuk N. 2021. Irreversible electroporation for prostate cancer. Life (Basel) 11(6): 490, PMID: 34071934. DOI: 10.3390/life11060490. CrossRefPubMedGoogle Scholar
Rubinsky B, Onik G and Mikus P. 2007. Irreversible electroporation: a new ablation modality – clinical implications. Technol Cancer Res Treat 6(1): 37-48, PMID: 17241099. DOI: 10.1177/153303460700600106. CrossRefPubMedGoogle Scholar
Valerio M, Stricker PD, Ahmed HU, Dickinson L, Ponsky L, Shnier R, Allen C and Emberton M. 2014. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis 17(4): 343-347, PMID: 25179590. DOI: 10.1038/pcan.2014.33. CrossRefPubMedGoogle Scholar
Guenther E, Klein N, Zapf S, Weil S, Schlosser C, Rubinsky B and Stehling MK. 2019. Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments. PLoS One 14(4): e0215093, PMID: 30986263. DOI: 10.1371/journal.pone.0215093. CrossRefPubMedGoogle Scholar
Collettini F, Enders J, Stephan C, Fischer T, Baur ADJ, Penzkofer T, Busch J, Hamm B and Gebauer B. 2019. Image-guided irreversible electroporation of localized prostate cancer: Functional and oncologic outcomes. Radiology 292(1): 250-257, PMID: 31161973. DOI: 10.1148/radiol.2019181987. CrossRefPubMedGoogle Scholar
Dong S, Wang H, Zhao Y, Sun Y and Yao C. 2018. First human trial of high-frequency irreversible electroporation therapy for prostate cancer. Technol Cancer Res Treat 17: 1533033818789692, PMID: 30045668. DOI: 10.1177/1533033818789692. CrossRefPubMedGoogle Scholar
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF and IMPACT Study Investigators. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5): 411-422, PMID: 20818862. DOI: 10.1056/NEJMoa1001294. CrossRefPubMedGoogle Scholar
Kim TJ and Koo KC. 2020. Current status and future perspectives of checkpoint inhibitor immunotherapy for prostate cancer: a comprehensive review. Int J Mol Sci 21(15): 5484, PMID: 32751945. DOI: 10.3390/ijms21155484. CrossRefPubMedGoogle Scholar
Provenge | European Medicines Agency. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/provenge [Last accessed on November 13, 2022]. Google Scholar
Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T and Mottet N. 2017. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4): 630-642, PMID: 27591931. DOI: 10.1016/j.eururo.2016.08.002. CrossRefPubMedGoogle Scholar
Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A and Kantoff PW. 2019. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol 37(13): 1051-1061, PMID: 30817251. DOI: 10.1200/JCO.18.02031. CrossRefPubMedGoogle Scholar
Janiczek M, Szylberg Ł, Kasperska A, Kowalewski A, Parol M, Antosik P, Radecka B and Marszałek A. 2017. Immunotherapy as a promising treatment for prostate cancer: a systematic review. J Immunol Res 4861570, 2017. PMID: 29109964. DOI: 10.1155/2017/4861570. CrossRefPubMedGoogle Scholar
Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A and Scher HI. 2019. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol 5(4): 471-478, PMID: 30589920. DOI: 10.1001/jamaoncol.2018.5801. CrossRefPubMedGoogle Scholar
Petrylak DP, Ratta R, Gafanov R, Facchini G, Piulats JM, Kramer G, Flaig TW, Chandana SR, Li B, Burgents J and Fizazi K. 2021. KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Future Oncol 17(25): 3291-3299, PMID: 34098744. DOI: 10.2217/fon-2020-1133. CrossRefPubMedGoogle Scholar
Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J and Sharma P. 2017. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23(5): 551-555, PMID: 28346412. DOI: 10.1038/nm.4308. CrossRefPubMedGoogle Scholar
Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR and CA184-043 Investigators. 2014. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15(7): 700-712, PMID: 24831977. DOI: 10.1016/S1470-2045(14)70189-5. CrossRefPubMedGoogle Scholar
Taghizadeh H, Marhold M, Tomasich E, Udovica S, Merchant A and Krainer M. 2019. Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives. Oncoimmunology 8(11): e1644109, PMID: 31646092. DOI: 10.1080/2162402X.2019.1644109. CrossRefPubMedGoogle Scholar
Marhold M, Kramer G, Krainer M and Le Magnen C. 2022. The prostate cancer landscape in Europe: Current challenges, future opportunities. Cancer Lett 526: 304-310, PMID: 34863887. DOI: 10.1016/j.canlet.2021.11.033. CrossRefPubMedGoogle Scholar
Lee H. 2022. Relative efficacy of (225)Ac-PSMA-617 and (177)Lu-PSMA-617 in prostate cancer based on subcellular dosimetry. Mol Imaging Radionucl Ther 31(1): 1-6, PMID: 35114745. DOI: 10.4274/mirt.galenos.2021.63308. CrossRefPubMedGoogle Scholar
Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, de Ridder C, Stuurman D, Konijnenberg MW, van Weerden WM, de Jong M and Nonnekens J. 2021. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging 48(5): 1339-1350, PMID: 33094433. DOI: 10.1007/s00259-020-05057-6. CrossRefPubMedGoogle Scholar
Zurth C, Koskinen M, Fricke R, Prien O, Korjamo T, Graudenz K, Denner K, Bairlein M, von Bühler CJ, Wilkinson G and Gieschen H. 2019. Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet 44(6): 747-759, PMID: 31571146. DOI: 10.1007/s13318-019-00577-5
CrossRefPubMedGoogle Scholar
Banerjee SR, Kumar V, Lisok A, Chen J, Minn I, Brummet M, Boinapally S, Cole M, Ngen E, Wharram B, Brayton C, Hobbs RF and Pomper MG. 2019. (177)Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. Eur J Nucl Med Mol Imaging 46(12): 2545-2557, PMID: 31399803. DOI: 10.1007/s00259-019-04434-0
CrossRefPubMedGoogle Scholar
Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, Linxweiler J, Bartholomä M and Ezziddin S. 2022. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging 49(3): 1075-1085, PMID: 34494131. DOI: 10.1007/s00259-021-05525-7
CrossRefPubMedGoogle Scholar
Tschan VJ, Borgna F, Busslinger SD, Stirn M, Rodriguez JMM, Bernhardt P, Schibli R and Müller C. 2022. Preclinical investigations using [(177)Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer. Eur J Nucl Med Mol Imaging 49(11): 3639-3650, PMID: 35635566. DOI: 10.1007/s00259-022-05837-2
CrossRefPubMedGoogle Scholar
Fendler WP, Stuparu AD, Evans-Axelsson S, Lückerath K, Wei L, Kim W, Poddar S, Said J, Radu CG, Eiber M, Czernin J, Slavik R and Herrmann K. 2017. Establishing (177)Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer. J Nucl Med 58(11): 1786-1792, PMID: 28546332. DOI: 10.2967/jnumed.117.193359. Abstract/FREE Full TextGoogle Scholar
Rathkopf DE and Scher HI. 2018. Apalutamide for the treatment of prostate cancer. Expert Rev Anticancer Ther 18(9): 823-836, PMID: 30101644. DOI: 10.1080/14737140.2018.1503954. CrossRefPubMedGoogle Scholar
Eberli D, Kranzbühler B, Prause L, Baumgartner V, Preda S, Sousa R, Lehner F and Salemi S. 2022. Apalutamide and autophagy inhibition in a xenograft mouse model of human prostate cancer. J Cancer Res Clin Oncol 148(12): 3351-3360, PMID: 35751683. DOI: 10.1007/s00432-022-04059-1. CrossRefPubMedGoogle Scholar
Saini NK, Gabani BB, Todmal U, Sulochana SP, Kiran V, Zainuddin M, Balaji N, Polina SB, Srinivas NR and Mullangi R. 2021. Pharmacokinetics of darolutamide in mouse – assessment of the disposition of the diastereomers, key active metabolite and interconversion phenomenon: implications to cancer patients. Drug Metab Lett 14(1): 54-65, 2021. PMID: 32436836. DOI: 10.2174/1872312814666200521091236. CrossRefPubMedGoogle Scholar
Nykänen P, Korjamo T, Gieschen H, Zurth C and Koskinen M. 2020. Pharmacokinetics of darolutamide, its diastereomers and active metabolite in the mouse: Response to Saini NK et al. (2020). Drug Metab Lett 14(1): 9-16, 2021. PMID: 33183216. D
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 RD-ICUAP
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Definir aviso de derechos.
Los datos de este artículo, así como los detalles técnicos para la realización del experimento, se pueden compartir a solicitud directa con el autor de correspondencia.
Los datos personales facilitados por los autores a RD-ICUAP se usarán exclusivamente para los fines declarados por la misma, no estando disponibles para ningún otro propósito ni proporcionados a terceros.
